MarginsXMarginsX
Home › Markets › Health Care › SAEN

Genenta Science S.p.A. (SAEN)

SAEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6000
-7.66% on the day
Market cap
$28.9M
Nano cap
Revenue
No annual revenue in SEC XBRL data for this filer
Net income
No annual revenue in SEC XBRL data for this filer

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerSAEN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryItaly
IPO year2021
SEC CIK0001838716

Financials

No annual revenue in SEC XBRL data for this filer.

Warning signs

Cash runway
9.7 months
$6.1M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed April 1, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-01
Cash and burn$6.1M cash; operating cash flow -$1.9M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-01-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDannible & McKee, LLP, Syracuse, New York, United StatesPCAOB Form AP 2026-04-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$7.2M-$7.6M$6.1M$8.4MNeeds four quarters20-F 2026-04-01

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-2.3%
1 month-10.0%
3 months-50.0%
Year to date-56.4%
1 year-70.2%
From 52-week high-70.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CVMCel-Sci Corporation$1.66+29.69%$29.2M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
PTHSPelthos Therapeutics Inc.$7.15-3.90%$28.1M
LONALeonaBio Inc.$3.23-6.92%$30.4M
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
ELUTElutia Inc.$0.8229+0.35%$36.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier